#1HYPERFINEⓇ Brain Imaging Within Reach The Swoop® system is driving the future of brain health. Corporate Deck - Sept 2023 Hyperfine, Swoop, and Portable MR Imaging are registered trademarks of Hyperfine, Inc. PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved.#2Forward-looking Statements This presentation includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results of Hyperfine, Inc. (the "Company") may differ from its expectations, estimates and projections and consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions (or the negative versions of such words or expressions) are intended to identify such forward-looking statements. These forward-looking statements include, without limitation, the Company's goals and commercial plans, the benefits of the Company's products and services, and the Company's future performance and its ability to implement its strategy. These for ard-looking statements involve significant risks and uncertainties that could cause the act results to differ materially from the expected results. Most of these factors are outside of the Company's control and are difficult to predict. Factors that may cause such differences include, but are not limited to: the success, cost and timing of the Company's product development and commercialization activities, including the degree that the Swoop® system is accepted and used by healthcare professionals; the impact of COVID-19 on the Company's business; the inability to maintain the listing of the Company's Class A common stock on the Nasdaq; the Company's inability to grow and manage growth profitably and retain its key employees; changes in applicable laws or regulations; the inability of the Company to raise financing in the future; the inability of the Company to obtain and maintain regulatory clearance or approval for its products, and any related restrictions and limitations of any cleared or approved product; the inability of the Company to identify, in-license or acquire additional technology; the inability of the Company to maintain its existing or future license, manufacturing, supply and distribution agreements and to obtain adequate supply of its products; the inability of the Company to compete with other companies currently marketing or engaged in the development of products and services that the Company is currently marketing or developing; the size and growth potential of the markets for the Company's products and services, and its ability to serve those markets, either alone or in partnership with others; the pricing of the Company's products and services and reimbursement for medical procedures conducted using the Company's products and services; the Company's estimates regarding expenses, revenue, capital requirements and needs for additional financing; the Company's financial performance; and other risks and uncertainties indicated from time to time in Company's filings with the Securities and Exchange Commission, including those under "Risk Factors" therein. The Company cautions readers that the foregoing list of factors is not exclusive and that readers should not place undue reliance upon any forward-looking statements, which speak only as of the date made. The Company does not undertake or accept any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based. 2 PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. HYPERFINEⓇ#33 Cost and access limit brain imaging today. Delays in MRI compromise care. Patients shouldn't wait. PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. Anytime. Anywhere. The Swoop system brings brain imaging within reach. HYPERFINE,#4The Swoop System is Ready to Transform Brain Imaging and Improve Brain Health 4 Clinically-relevant images with ultra-low-field MRI Safe at multiple sites of care First mover with proprietary technology and Al-powered software Platform technology designed for multiple brain imaging applications PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. 200kg 430 MAX AA0900 HYPERFINE Affordable and cost-effective with global accessible reach FDA-cleared and commercially available in the US with reimbursement under existing CPT codes Global footprint through research institutions and the Bill & Melinda Gates Foundation Unity network HYPERFINEⓇ#5A First for Brain Health Hyperfine, Inc. has reimagined brain imaging with the Swoop system- a powerful brain imaging platform that physicians can use to make clinical decisions when and where it matters most. 5 PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved.#6Advancing the Care Experience for All 6 Hyperfine, Inc. is at the forefront of making healthcare more connected, portable, patient-centric, and accessible in less resource-intensive settings. 1 Patients Because empowered patient choices matter. BO PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. Clinicians and Care Teams Because timely decisions and personalized care matter. Hospitals Because resources and cost matter. HYPERFINEⓇ#7A New Paradigm in the Economics, Value, and Safety of Brain Imaging Low Up-front Capital No Construction or Installation Required 7 Minimal Recurring Costs No Need for Certified Operators Limited Staff Disruption Soft Tissue Characterization Patient Safety: lonizing Radiation, Heating, Transport Risk Conventional MRI PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. Swoop System CT Scanner HYPERFINEⓇ#8A Dramatic Improvement in Clinical Workflow The Swoop system streamlines the workflow process to enable timely clinical decisions and reduce risks. 8 Conventional MRI 22 Steps 1.0¹-11.2² Hours High Risk Swoop System PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. 3 Steps 0.5¹ 4.52 Hours Low Risk 1. Mazurek, M.H., Cahn, B.A., Yuen, M.M. et al. Portable, bedside, low-field magnetic resonance imaging for evaluation of intracerebral hemorrhage. Nat Commun 12, 5119 (2021). https://doi.org/10.1038/s41467-021-25441-6 2. Kuoy et al. Point-of-Care Brain MRI: Preliminary Results from a Single-Center Retrospective Study. Radiology 2022 https://doi.org/10.1148/radiol.211721 55% Time Reduction² HYPERFINEⓇ#9The Swoop System Enables Brain Imaging Anywhere 9 Current Paradigm Conventional MRI New Paradigm g Point of Care PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. Tojo Community Access NB Inpatient Outpatient Pre-hospital Epidemiological Studies ED ICU, Floor Division Clinics Remote / Low Resource Areas Low/Middle Income Countries Courtesy of William T. Kimberly, and Kevin Sheth, MD. Multiple sites of service and many applications to address significant unmet needs for care globally. HYPERFINE.#10Immediate Clinical Applications, Blueprint for Continued Growth Current Commercial and Clinical Applications Clinical Research and R&D for Future Applications 10 m Critical Care Pediatrics Stroke PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. Alzheimer's Future Opportunities Remote Care Delivery Global Expansion New Use Cases The Swoop system expands the fast growing (6% annual CAGR) $35 billion global imaging market. HYPERFINE.#11Deep Foundation to Drive Long-term Success 0000 Clinical Proof HYPERFINEⓇ Regulatory Excellence 11 PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. X Ecosystem of Support Rapid Innovation HYPERFINEⓇ#12Clinical Proof: Twenty-five Peer-Reviewed Publications to Date and Significant Investment in Studies in New Clinical Use Cases American Journal of Neuroradiology, April 2022 Implementation of a Low-Field Portable MRI Scanner in a Resource- Constrained Environment: Our Experience in Malawi Acquired >260 brain scans; concluded use may lead to faster diagnosis and expedited treatment, including in comatose patients in the E.D. and bed-bound patients with sudden onset neurologic deficits Science Advances, April 2022 Portable, Low-Field MRI Enables Highly Accessible and Dynamic Bedside Evaluation of Ischemic Stroke Imaged 50 confirmed acute ischemic stroke patients; accurately detected infarcts in 45 (90%) ; captured lesions as small as 4mm Nature Communications, August 2021 Portable, Bedside, Low-Field Magnetic Resonance Imaging for Evaluation of Intracerebral Hemorrhage Imaged >140 patients and correctly identified ICH in over 80% of confirmed cases 12 PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. Key Observational Studies Pursuing Multiple Clinical Applications ACTION PMR (Stroke) • HOPE PMR (Hydrocephalus) • SAFE MRI (ECMO) ● HYPERFINEⓇ#13Regulatory Excellence: Success in Multiple Geographies USA 2020 The Swoop system is cleared for brain imaging of patients of all ages. Eight FDA clearances since 2020. Most recently cleared under K230208. *Not yet commercialized 13 European Union* 2023 The Swoop system has CE certification for the European Union. ● ● United Kingdom* 2022 The Swoop system has UKCA certification for the United Kingdom. KM ● PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. Canada 2021 The Swoop system is approved for commercial sale in Canada. (Health Canada License 107054) NZ ZN Broad indi tion for imaging of the brain. Eight FDA clearances for the Swoop system in the last 36 months. CE certification achieved under latest MDR regulations. Australia 2022 The Swoop system is approved for commercial sale in Australia. (TGA ARTG Identifier 384545) NZ ZN New Zealand 2022 The Swoop system notified to WAND database and available for commercial sale in New Zealand. HYPERFINE.#14Ecosystem of Support: Scalable, Low-cost, Connected, and Customer-centric 14 Connectivity to integrate across radiology information systems Over-the-air software upgrades to enable rapid enhancements PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. Cloud for image and data viewing M (H) Cybersecurity: HITRUST and SOC2 type1 certifications Remote technical support and service to maximize customer uptime HYPERFINEⓇ#15Rapid innovation: Proven Record of Releasing New Technology to the Market a S 15 Al-powered Imaging 2020 SONO 2021 010110 101100 Hardware (1.7) and software (8.1): Brain imaging for all ages. 010110 101100 Hardware (1.6) and software (8.0): The world's first bedside MRI system for brain imaging of patients ages 2 and up. 2022 Hardware (1.8) and software (8.2): Additional automatic alignment and motion correction features. PROPERTY OF HYPERFINE, INC. ©2023. All rights reserved. 010110 101100 2023 010110 101100 Software (8.3): Elevated diagnostic value: advanced image reconstruction leveraging deep learning for T1, T2, and FLAIR sequences. Software (8.6): Significant DWI improvements, Advanced motion compensation. Software (8.5): DWI image quality improvement, improved intensity uniformity, faster image acquisition. Hardware (1.9): Updates to hardware components and minimum patient weight limit. Software (8.4): Fast T2: 50% faster option to the existing higher-quality T2 sequence. T1 (Standard): better intraparenchymal visibility, improved noise cancellation. E Strong IP portfolio with over 150 patents worldwide HYPERFINEⓇ